Mutants at the 2-Fold Interface of Adeno-associated Virus Type 2 (AAV2) Structural Proteins Suggest a Role in Viral Transcription for AAV Capsids

Journal of Virology

Volumn 90, Issue 16, 2016, Pages 7196-7204

  Aydemir, Fikret ^a   Salganik, Maxim ^a,b   Resztak, Justyna ^a,c   Singh, Jasbir ^a   Bennett, Antonette ^a   Agbandje McKenna, Mavis ^a   Muzyczka, Nicholas ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b BioTheranostics Inc   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; VIRUS DNA; VIRAL PROTEIN; VIRUS RNA;

ADENO ASSOCIATED VIRUS 2; ARTICLE; BINDING SITE; CONTROLLED STUDY; DNA BINDING; GENE DOSAGE; GENE EXPRESSION; GENETIC COMPLEMENTATION; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA SYNTHESIS; SEQUENCE ALIGNMENT; VIRUS CAPSID; VIRUS PARTICLE; VIRUS TRANSCRIPTION; AMINO ACID SUBSTITUTION; CHEMISTRY; DEPENDOPARVOVIRUS; GENETIC TRANSCRIPTION; GENETICS; HEK293 CELL LINE; HELA CELL LINE; HUMAN; METABOLISM; MOLECULAR MODEL; MUTATION; PARVOVIRUS INFECTION; PHENOTYPE; PHYSIOLOGY; VIRION; VIROLOGY; VIRUS GENOME;

AMINO ACID SUBSTITUTION; CAPSID; DEPENDOVIRUS; GENOME, VIRAL; HEK293 CELLS; HELA CELLS; HUMANS; MODELS, MOLECULAR; MUTATION; PARVOVIRIDAE INFECTIONS; PHENOTYPE; RNA, VIRAL; TRANSCRIPTION, GENETIC; VIRAL STRUCTURAL PROTEINS; VIRION;

EID: 84982214236     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00493-16     Document Type: Article

References (21)

1. Agbandje-McKenna M, Kleinschmidt J. 2011. AAV capsid and cell interactions, p 47-92. In Snyder RO, Moullier P (ed), Adeno-associated virus: methods and protocols. Humana Press, Totowa, NJ.
2. Samulski RJ, Muzyczka N. 2014. AAV-mediated gene therapy for research and therapeutic purposes. Annu Rev Virol 1:427-451. http://dx.doi.org/10.1146/annurev-virology-031413-085355.
3. Lochrie MA, Tatsuno GP, Christie B, McDonnell JW, Zhou S, Surosky R, Pierce GF, Colosi P. 2006. Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization. J Virol 80:821-834. http://dx.doi.org/10.1128/JVI.80.2.821-834 .2006.
4. Wu P, Xiao W, Conlon T, Hughes J, Agbandje-McKenna M, Ferkol T, Flotte T, Muzyczka N. 2000. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J Virol 74:8635-8647. http://dx.doi.org/10.1128/JVI.74 .18.8635-8647.2000.
5. Nam HJ, Gurda BL, McKenna R, Potter M, Byrne B, Salganik M, Muzyczka N, Agbandje-McKenna M. 2011. Structural studies of adeno-associated virus serotype 8 capsid transitions associated with endosomal trafficking. J Virol 85:11791-11799. http://dx.doi.org/10 .1128/JVI.05305-11.
6. Salganik M, Aydemir F, Nam HJ, McKenna R, Agbandje-McKenna M, Muzyczka N. 2014. Adeno-associated virus capsid proteins may play a role in transcription and second-strand synthesis of recombinant genomes. J Virol 88:1071-1079. http://dx.doi.org/10.1128/JVI.02093-13.
7. Zhong L, Li B, Mah CS, Govindasamy L, Agbandje-McKenna M, Cooper M, Herzog RW, Zolotukhin I, Warrington KH, Jr, Weigel-Van Aken KA, Hobbs JA, Zolotukhin S, Muzyczka N, Srivastava A. 2008. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci U S A 105:7827-7832. http://dx.doi.org/10.1073 /pnas.0802866105.
8. Schneider CA, Rasband WS, Eliceiri KW. 2012. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9:671-675. http://dx.doi.org/10 .1038/nmeth.2089.
9. Grimm D, Kern A, Rittner K, Kleinschmidt JA. 1998. Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum Gene Ther 9:2745-2760. http://dx.doi.org/10.1089/hum.1998.9.18-2745.
10. Sonntag F, Bleker S, Leuchs B, Fischer R, Kleinschmidt JA. 2006. Adeno-associated virus type 2 capsids with externalized VP1/VP2 trafficking domains are generated prior to passage through the cytoplasm and are maintained until uncoating occurs in the nucleus. J Virol 80:11040-11054. http://dx.doi.org/10.1128/JVI.01056-06.
11. Wobus CE, Hugle-Dorr B, Girod A, Petersen G, Hallek M, Kleinschmidt JA. 2000. Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J Virol 74:9281-9293. http://dx.doi.org/10.1128/JVI.74.19.9281 -9293.2000.
12. McCraw DM, O'Donnell JK, Taylor KA, Stagg SM, Chapman MS. 2012. Structure of adeno-associated virus-2 in complex with neutralizing monoclonal antibody A20. Virology 431:40-49. http://dx.doi.org/10 .1016/j.virol.2012.05.004.
13. Bevington JM, Needham PG, Verrill KC, Collaco RF, Basrur V, Trempe JP. 2007. Adeno-associated virus interactions with B23/nucleophosmin: identification of sub-nucleolar virion regions. Virology 357:102-113. http://dx.doi.org/10.1016/j.virol.2006.07.050.
14. Murphy SL, Bhagwat A, Edmonson S, Zhou S, High KA. 2008. Highthroughput screening and biophysical interrogation of hepatotropic AAV. Mol Ther 16:1960-1967 http://dx.doi.org/10.1038/mt.2008.210.
15. Qiu J, Brown KE. 1999. A 110-kDa nuclear shuttle protein, nucleolin, specifically binds to adeno-associated virus type 2 (AAV-2) capsid. Virology 257:373-382 http://dx.doi.org/10.1006/viro.1999.9664.
16. Schreiber CA, Sakuma T, Izumiya Y, Holditch SJ, Hickey RD, Bressin RK, Basu U, Koide K, Asokan A, Ikeda Y. 2015. An siRNA screen identifies the U2 snRNP spliceosome as a host restriction factor for recombinant adeno-associated viruses. PLoS Pathog 11:e1005082 http://dx.doi .org/10.1371/journal.ppat.1005082.
17. Strobel B, Miller FD, Rist W, Lamla T. 2015. Comparative analysis of cesium chloride-and iodixanol-based purification of recombinant adenoassociated viral vectors for preclinical applications. Hum Gene Ther Methods 26:147-157 http://dx.doi.org/10.1089/hgtb.2015.051.
18. Akusjarvi G, Stevenin J. 2003. Remodelling of the host cell RNA splicing machinery during an adenovirus infection. Curr Top Microbiol Immunol 272:253-286.
19. Salganik M, Venkatakrishnan B, Bennett A, Lins B, Yarbrough J, Muzyczka N, Agbandje-McKenna M, McKenna R. 2012. Evidence for pH-dependent protease activity in the adeno-associated virus capsid. J Virol 86:11877-11885 http://dx.doi.org/10.1128/JVI.01717-12.
20. Kronenberg S, Bottcher B, von der Lieth CW, Bleker S, Kleinschmidt JA. 2005. A conformational change in the adeno-associated virus type 2 capsid leads to the exposure of hidden VP1 N termini. J Virol 79:5296-5303 http://dx.doi.org/10.1128/JVI.79.9.5296-5303.2005.
21. Popa-Wagner R, Porwal M, Kann M, Reuss M, Weimer M, Florin L, Kleinschmidt JA. 2012. Impact of VP1-specific protein sequence motifs on adeno-associated virus type 2 intracellular trafficking and nuclear entry. J Virol 86:9163-9174 http://dx.doi.org/10.1128/JVI.00282-12.